Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Cowden, Jeffery M ^a   Riley, Jason P ^a   Ma, Jing Y ^a   Thurmond, Robin L ^a   Dunford, Paul J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; COLLAGEN; HISTAMINE H4 RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; 1 ((5 CHLORO 1H INDOL 2 YL)CARBONYL) 4 METHYLPIPERAZINE; 1-((5-CHLORO-1H-INDOL-2-YL)CARBONYL)-4-METHYLPIPERAZINE; ANTIBODY; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; G PROTEIN COUPLED RECEPTOR; HISTAMINE RECEPTOR; HRH4 PROTEIN, MOUSE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL HYPERPLASIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GOBLET CELL HYPERPLASIA; IMMUNE DYSREGULATION; IMMUNOMODULATION; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; RECEPTOR BLOCKING; RESPIRATORY TRACT INFLAMMATION; TH2 CELL; AIRWAY REMODELING; ANIMAL; BAGG ALBINO MOUSE; BRONCHUS HYPERREACTIVITY; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GOBLET CELL; HYPERPLASIA; IMMUNOLOGY; INHALATION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AIRWAY REMODELING; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHIAL PROVOCATION TESTS; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GOBLET CELLS; HISTAMINE ANTAGONISTS; HYPERPLASIA; INDOLES; INFLAMMATION MEDIATORS; INTERLEUKIN-13; INTERLEUKIN-5; MICE; MICE, INBRED BALB C; OVALBUMIN; PIPERAZINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, HISTAMINE; TH2 CELLS;

EID: 77956706418     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-86     Document Type: Article

References (39)

1. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From Bronchoconstriction to Airways Inflammation and Remodeling. Am J Respir Crit Care Med 2000, 161:1720-1745.
2. Busse WW, Lemanske RF. Asthma. N Engl J Med 2001, 344:350-362. 10.1056/NEJM200102013440507, 11172168.
3. Hammad H, Lambrecht BN. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J Allergy Clin Immunol 2006, 118:331-336. 10.1016/j.jaci.2006.03.041, 16890754.
4. Casale T, Wood D, Richerson H, Trapp S, Metzger W, Zavala D, Hunninghake G. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987, 79:1197-1203. 10.1172/JCI112937, 424309, 3549781.
5. Jarjour N, Calhoun W, Schwartz L, Busse W. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis 1991, 144:83-87.
6. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The Histamine H4 Receptor Mediates Allergic Airway Inflammation by Regulating the Activation of CD4+ T Cells. J Immunol 2006, 176:7062-7070.
7. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7:41-53. 10.1038/nrd2465, 18172439.
8. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: Central Mediator of Allergic Asthma. Science 1998, 282:2258-2261. 10.1126/science.282.5397.2258, 9856949.
9. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999, 103:779-788. 10.1172/JCI5909, 408149, 10079098.
10. Jablonowski JA, Grice CA, Chai W, Dvorak CA, Venable JD, Kwok AK, Ly KS, Wei J, Baker SM, Desai PJ, et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 2003, 46:3957-3960. 10.1021/jm0341047, 12954048.
11. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung W-P, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, et al. A Potent and Selective Histamine H4 Receptor Antagonist with Anti-Inflammatory Properties. J Pharmacol Exp Ther 2004, 309:404-413. 10.1124/jpet.103.061754, 14722321.
12. Hantos Z, Adamicza A, Govaerts E, Daroczy B. Mechanical impedances of lungs and chest wall in the cat. J Appl Physiol 1992, 73:427-433.
13. Tomioka S, Bates JHT, Irvin CG. Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations. J Appl Physiol 2002, 93:263-270.
14. Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, Rafferty P, Lakshminarayanan M, Griswold DE, Bugelski PJ, Das AM. Therapeutic Dosing with Anti-Interleukin-13 Monoclonal Antibody Inhibits Asthma Progression in Mice. J Pharmacol Exp Ther 2005, 313:8-15. 10.1124/jpet.104.076133, 15644434.
15. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000, 192:455-462. 10.1084/jem.192.3.455, 2193222, 10934234.
16. Youssef LA, Schuyler M, Gilmartin L, Pickett G, Bard JDJ, Tarleton CA, Archibeque T, Qualls C, Wilson BS, Oliver JM. Histamine Release from the Basophils of Control and Asthmatic Subjects and a Comparison of Gene Expression between "Releaser" and "Nonreleaser" Basophils. J Immunol 2007, 178:4584-4594.
17. Xu X, Zhang D, Zhang H, Wolters PJ, Killeen NP, Sullivan BM, Locksley RM, Lowell CA, Caughey GH. Neutrophil histamine contributes to inflammation in mycoplasma pneumonia. The Journal of Experimental Medicine 2006, 203:2907-2917. 10.1084/jem.20061232, 2118183, 17158962.
18. Lima C, Souza VMO, Soares AL, Macedo MS, Tavares-de-Lima W, Vargaftig BB. Interference of methysergide, a specific 5-hydroxytryptamine receptor antagonist, with airway chronic allergic inflammation and remodelling in a murine model of asthma. Clinical & Experimental Allergy 2007, 37:723-734.
19. Ma Y, HayGlass KT, Becker AB, Fan Y, Yang X, Basu S, Srinivasan G, Simons FER, Halayko AJ, Peng Z. Novel Recombinant Interleukin-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice. Am J Respir Crit Care Med 2007, 176:439-445. 10.1164/rccm.200610-1405OC, 17556715.
20. Walter DM, McIntire JJ, Berry G, McKenzie ANJ, Donaldson DD, DeKruyff RH, Umetsu DT. Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity. J Immunol 2001, 167:4668-4675.
21. Bates JHT, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003, 94:1297-1306.
22. Sakai K, Yokoyama A, Kohno N, Hamada HK. Prolonged Antigen Exposure Ameliorates Airway Inflammation But Not Remodeling in a Mouse Model of Bronchial Asthma. Int Arch Allergy Appl Immunol 2001, 126:126-134.
23. Koya T, Kodama T, Takeda K, Miyahara N, Yang E-S, Taube C, Joetham A, Park J-W, Dakhama A, Gelfand EW. Importance of Myeloid Dendritic Cells in Persistent Airway Disease after Repeated Allergen Exposure. Am J Respir Crit Care Med 2006, 173:42-55. 10.1164/rccm.200505-783OC, 2662981, 16192450.
24. Schaller MA, Kallal LE, Lukacs NW. A Key Role for CC Chemokine Receptor 1 in T-Cell-Mediated Respiratory Inflammation. Am J Pathol 2008, 172:386-394. 10.2353/ajpath.2008.070537, 2312366, 18202190.
25. Gupta S, Fuchs B, Schulz-Maronde S, Heitland A, Escher SE, Mack M, Tillmann H-C, Braun A, Forssmann W-G, Elsner J, Forssmann U. Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation. J Leukoc Biol 2008, 83:765-773. 10.1189/jlb.0607429, 18063698.
26. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, Hall D, Bessant C, Bartholomew M, Howarth PH, et al. Chemokine Receptor 4 Plays a Key Role in T Cell Recruitment into the Airways of Asthmatic Patients. J Immunol 2010, 184:4568-4574. 10.4049/jimmunol.0901342, 20237293.
27. Garlisi CG, Falcone A, Billah NM, Egan RW, SP U. T cells are the predominant source of interleukin-5 but not interleukin-4 mRNA expression in the lungs of antigen-challenged allergic mice. Am J Respir Cell Mol Biol 1996, 15:420-428.
28. Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, Cruikshank WW. Histamine 4 Receptor Activation Induces Recruitment of FoxP3+ T Cells and Inhibits Allergic Asthma in a Murine Model. J Immunol 2007, 178:8081-8089.
29. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB. Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 2002, 303:300-307. 10.1124/jpet.102.036939, 12235264.
30. Gutzmer R, Diestel C, Mommert S, Koether B, Stark H, Wittmann M, Werfel T. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005, 174:5224-5232.
31. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 Receptor in Moderate Atopic Asthma. A Phase I/II Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
32. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970. 10.1067/mai.2001.115624, 11398072.
33. Leckie MJ, Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148. 10.1016/S0140-6736(00)03496-6, 11191542.
34. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA. Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma: A Pilot Study. Am J Respir Crit Care Med 2003, 167:1655-1659. 10.1164/rccm.200206-525OC, 12649124.
35. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, Robinson D, Wenzel S, Busse W, Hansel TT, et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med 2007, 176:1062-1071. 10.1164/rccm.200701-085OC, 17872493.
36. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. The Lancet 2007, 370:1422-1431.
37. Tamaoki J, Kondo M, Sakai N, Aoshiba K, Tagaya E, Nakata J, Isono K, Nagai A. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Lancet 2000, 356:273-278. 10.1016/S0140-6736(00)02501-0, 11071181.
38. Sano Y, Suzuki N, Yamada H, To Y, Ogawa C, Ohta K, Adachi M. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J Allergy Clin Immunol 2003, 111:958-966. 10.1067/mai.2003.1415, 12743558.
39. Hoshino M, Fujita Y, Saji J, Inoue T, Nakagawa T, Miyazawa T. Effect of suplatast tosilate on goblet cell metaplasia in patients with asthma. Allergy 2005, 60:1394-1400. 10.1111/j.1398-9995.2005.00897.x, 16197471.